Changes in systemic medication in children and adolescents with JIA: why, when and which patterns
Authors' conclusion
JIA medication is mostly changed because of inefficacy in the first treatment line (predominantly MTX) vs remission in the second treatment line (roughly half on bDMARDs).
Study context
- Population
- JIA patients starting first-line systemic therapy, Dutch tertiary paediatric rheumatology centre1,422 treatment lines
- Participants
- 551 patients
- Outcome
- Frequencies and timing of reasons for change in systemic medication, across treatment lines
Methodological detailssingle-centre, tertiary paediatric rheumatology centre, Sankey diagram, cumulative incidences Fine-Gray models
- Single-centre
- Tertiary paediatric rheumatology centre
- Sankey diagram
- Cumulative incidences Fine-Gray models
Main finding
As reported in the abstract
Reasons for change in JIA medication by treatment line
Change because of inefficacy, first treatment line
42.9%
Change because of remission, second treatment line
46.2%
Observational data: associations, not effects.
Further findings
Treatment lines per patient
- Median number of treatment lines per patient (IQR 1-3)
- 2
Drugs used by treatment line
- MTX as first treatment line
- 89.1%
- bDMARDs as next treatment line
- 53.3%
Original publication
Changes in systemic medication in children and adolescents with JIA: why, when and which patterns. Rheumatology (Oxford). Published 10 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →